How will RNAi facilitate drug development? (Q33220982)

24 July 2017

1 reference

title

How will RNAi facilitate drug development? (English)

1 reference

24 July 2017

Steven Bartz

1

1 reference

24 July 2017

Aimee L Jackson

series ordinal

2

1 reference

24 July 2017

publication date

2 August 2005

1 reference

Science's STKE : signal transduction knowledge environment

24 July 2017

published in

1 reference

24 July 2017

volume

2005

1 reference

24 July 2017

issue

295

1 reference

24 July 2017

page(s)

pe39

1 reference

Mechanisms of gene silencing by double-stranded RNA

24 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screens

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Identification of Modulators of TRAIL-Induced Apoptosis via RNAi-Based Phenotypic Screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

An endoribonuclease-prepared siRNA screen in human cells identifies genes essential for cell division

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

A large-scale RNAi screen in human cells identifies new components of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

A resource for large-scale RNA-interference-based screens in mammals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Dissecting Wnt/beta-catenin signaling during gastrulation using RNA interference in mouse embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Inhibition of hepatitis B virus in mice by RNA interference

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Expression profiling reveals off-target gene regulation by RNAi

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSTKE.2952005PE39

21 January 2018

Identifiers

DOI

10.1126/STKE.2952005PE39

1 reference

24 July 2017

1 reference